The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
EMBARK: Testosterone recovery to >250 ng/dL following treatment suspension.
 
Stephen Freedland
Employment - Genomic Health (I)
Stock and Other Ownership Interests - Caper Labs; Hessian Labs
Honoraria - Astellas Pharma; Pfizer
Consulting or Advisory Role - A3P Biomedical; Astellas Pharma; AstraZeneca; Bayer; Caper Labs; Clovis Oncology; Dendreon; Exact Sciences; Exosome Diagnostics; Ferring; Hessian Labs; Janssen Biotech; Lilly; LynxDx; Merck; Myovant Sciences; Novartis; Pfizer; Sanofi; Tempus; Tolmar
Speakers' Bureau - AstraZeneca; Sanofi
Research Funding - Bayer (Inst); Diasorin; GenomeDx (Inst); Janssen Biotech (Inst); MDxHealth (Inst); Merck; Myriad Genetics (Inst); OPKO Diagnostics (Inst); Progenika (Inst)
Travel, Accommodations, Expenses - Sanofi
 
Ronald Tutrone
Employment - Chesapeake Urology
Stock and Other Ownership Interests - Compass Therapeutics; GlaxoSmithKline; ImmnityBio; Novartis; Urogen pharma; Veru
Consulting or Advisory Role - Exosome Diagnostics; Myovant Sciences; Novartis; Nymox
Speakers' Bureau - Medivation/Astellas; Pfizer
Research Funding - Advantagene (Inst); Arvinas (Inst); AstraZeneca (Inst); Bayer (Inst); Blue Earth Diagnostics (Inst); Dendreon (Inst); ESSA (Inst); Exosome Diagnostics (Inst); Francis Medical (Inst); Genomic Health (Inst); Janssen Oncology (Inst); Lantheus Medical Imaging (Inst); Lilly (Inst); MDxHealth (Inst); Medivation/Astellas (Inst); Merck (Inst); POINT Biopharma (Inst); Propella Therapeutics (Inst)
 
Fred Saad
Honoraria - Abbvie; Advanced Accelerator Applications; Astellas Pharma; AstraZeneca; Bayer; BMS; GlaxoSmithKline; Janssen Oncology; Knight Therapeutics; Merck; Myovant Sciences; Novartis; Pfizer; Sanofi; Sumitomo Dainippon Pharma Oncology; Tolmar
Consulting or Advisory Role - Abbvie; Advanced Accelerator Applications; Astellas Pharma; AstraZeneca/MedImmune; Bayer; GlaxoSmithKline; Janssen Oncology; Knight Therapeutics; Myovant Sciences; Novartis; Pfizer; Sanofi; Sumitomo Dainippon Pharma Oncology; Tolmar
Research Funding - Abbvie (Inst); Advanced Accelerator Applications (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Point Therapeutics (Inst); Sanofi (Inst)
 
Michael Cookson
Honoraria - Astellas Pharma; Bayer; Lantheus Medical Imaging; Myovant Sciences; Remedica Medical Education & Publishing
Consulting or Advisory Role - Bayer; Cleveland Diagnostics; Janssen Biotech; LynxDx; Nonagen Bioscience; Pfizer; Prokarium; Propella Therapeutics; Signatera; Urogen pharma
Research Funding - Ferring (Inst); MDxHealth (Inst)
 
Daniel Saltzstein
Consulting or Advisory Role - Astellas Pharma; Johnson & Johnson; Medivation
Speakers' Bureau - Astellas Pharma; Johnson & Johnson; Medivation
 
Stephanie Chan
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Fong Wang
Employment - Exelixis; Pfizer
Stock and Other Ownership Interests - Exelixis; Pfizer
Research Funding - Exelixis; Pfizer
Travel, Accommodations, Expenses - Exelixis; Pfizer
 
Matt Rosales
Employment - Astellas Pharma
Stock and Other Ownership Interests - Astellas Pharma
Research Funding - Astellas Pharma
Travel, Accommodations, Expenses - Astellas Pharma
 
Ruslan Croitoru
No Relationships to Disclose
 
Neal Shore
Stock and Other Ownership Interests - Photocure
Consulting or Advisory Role - Accord Research; Alessa Therapeutics; Amgen; Antev; Asieris Pharmaceuticals; Astellas Pharma; AstraZeneca; Aura Biosciences; Bayer; Bioprotect; Bristol-Myers Squibb/Sanofi; CG Oncology; Clarity Pharmaceuticals; Dendreon; Exact Imaging; Ferring; Fize Medical; Glytherix; ImmunityBio; InVitae; Janssen Scientific Affairs; Lantheus Medical Imaging; Lilly; MDxHealth; Medivation/Astellas; Merck; Minomic; Myriad Genetics; Novartis; Nusano; Pfizer; Photocure; PlatformQ Health; Promaxo; Protara Therapeutics; Sanofi; Siemens; Speciality Networks; Sumitomo Pharma Oncology; Telix Pharmaceuticals; Tolmar; Tutelix; Urogen pharma
Research Funding - Abbvie; Advantagene; Amgen; Aragon Pharmaceuticals; Astellas Pharma; AstraZeneca; Bayer; Boston Scientific; Bristol-Myers Squibb/Pfizer; CG Oncology; Clovis Oncology; Dendreon; DisperSol; Endocyte; Exact Imaging; Exelixis; Ferring; FKD Therapies; FORMA Therapeutics; Foundation Medicine; Genentech; Guardant Health; InVitae; Istari Oncology; Janssen; Jiangsu Yahong Meditech; MDxHealth; Medivation; Merck; MT Group; Myovant Sciences; Myriad Genetics; Novartis; Nymox; OncoCellMDx; ORIC Pharmaceuticals; pacific edge; Palette Life Sciences; Pfizer; Plexxikon; POINT Biopharma; Propella Therapeutics; Propella Therapeutics; RhoVac; Sanofi; SeaGen; Sesen Bio; Steba Biotech; Theralase; Tolmar; Urogen pharma; Urotronic; US Biotest; Vaxiion; Veru; Zenflow